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Integration of machine learning
and mechanistic models accurately
predicts variation in cell density of
glioblastoma using multiparametric
MRI
Nathan Gaw1, Andrea Hawkins-Daarud 2, Leland S. Hu3, Hyunsoo Yoon 1,
Lujia Wang1, Yanzhe Xu 1, Pamela R. Jackson2, Kyle W. Singleton 2, Leslie C. Baxter3,
Jennifer Eschbacher4, Ashlyn Gonzales3, Ashley Nespodzany3, Kris Smith 5, Peter Nakaji5,
J. Ross Mitchell 6, Teresa Wu1, Kristin R. Swanson2,7 & Jing Li1
Glioblastoma (GBM) is a heterogeneous and lethal brain cancer. These tumors are followed using
magnetic resonance imaging (MRI), which is unable to precisely identify tumor cell invasion, impairing
effective surgery and radiation planning. We present a novel hybrid model, based on multiparametric
intensities, which combines machine learning (ML) with a mechanistic model of tumor growth to
provide spatially resolved tumor cell density predictions. The ML component is an imaging data-driven
graph-based semi-supervised learning model and we use the Proliferation-Invasion (PI) mechanistic
tumor growth model. We thus refer to the hybrid model as the ML-PI model. The hybrid model was
trained using 82 image-localized biopsies from 18 primary GBM patients with pre-operative MRI
using a leave-one-patient-out cross validation framework. A Relief algorithm was developed to
quantify relative contributions from the data sources. The ML-PI model statistically significantly
outperformed (p < 0.001) both individual models, ML and PI, achieving a mean absolute predicted error
(MAPE) of 0.106 ± 0.125 versus 0.199 ± 0.186 (ML) and 0.227 ± 0.215 (PI), respectively. Associated
Pearson correlation coefficients for ML-PI, ML, and PI were 0.838, 0.518, and 0.437, respectively. The
Relief algorithm showed the PI model had the greatest contribution to the result, emphasizing the
importance of the hybrid model in achieving the high accuracy.
Gadolinium contrast-enhanced T1-weighted (T1Gd) MRI serves as the clinical standard for guiding surgical
resection and radiation therapy in glioblastoma (GBM), an aggressive primary brain tumor. While the contrast enhancement on a T1Gd MRI highlights the areas of a disrupted blood-brain-barrier and not the tumor
cells directly1, this physiological disturbance does generally correlate with regions of higher tumor cell density2.
Unfortunately, this rule-of-thumb correlation is not accurate enough to ensure that spatially targeted therapies,
guided by the T1Gd, will provide optimal outcomes. More globally, this non-specificity impacts the ability to
interpret how a given tumor responded to therapy, causing doubt in therapeutic decisions throughout the course
of the disease1,3,4. Indeed, a wealth of evidence has shown that MRI enhancement underestimates true tumor
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burden, due to poor delineation of invasive tumor regions with intact BBB5–8, and that resection (better able to
target the bulk of the tumor) results in an increase in overall survival9. These non-enhancing tumor populations
can represent a substantial proportion of overall disease burden7,9, yet typically remain unresected (by surgery)
and undertreated (by radiation), thereby leading to universal recurrence and poor survival.
There have been a number of attempts to use other types of clinical imaging to directly show the tumor invasion. Perhaps the most common is the Apparent Diffusion Coefficient (ADC) map, generated from diffusion
MRI, which has previously been shown to inversely correlate with cell density10–12. However, this relationship
to overall cell density is not easily converted to tumor cell density only, which is the primary variable of interest
in the invasive rim of the tumor. Unfortunately, this uncertain area is the main region of interest for expanding
spatially targeted therapies. Radio-labeled tracers used with positron emission tomography (PET) can also highlight actively proliferating regions within the brain13–15. While promising, the resolution of PET scans are not
nearly as accurate for surgical planning as MRI and these scans are also more difficult to obtain due to the use of
non-standard tracers with shorter half-lives and the need of a PET scanner16. In this paper, we present a hybrid
method, consisting of machine learning and mechanistic model components, for predicting specifically the tumor
cell density based on multi-parametric MRI.
Machine learning (ML) approaches have been gaining popularity in trying to elucidate tumor characteristics using radiological features17–22. Due to the limited data regarding spatial localization of tissue specimens
(biopsies) from tumors typically collected, previous radiomics models have primarily aimed at categorizing the
entirety of a tumor according to a given label derived from a single tissue sample, i.e. IDH1mut status, MGMT
methylation status, or Verhaak tumor type17,18,23. We have made use of a unique data set consisting of multiple
image-localized biopsies from 18 patients to enable spatially heterogeneous predictions of tumor cell density
throughout an individual tumor.
Our approach is further unique in that it brings together the strengths of both machine learning (ML) and
mechanistic models (MM). ML is very powerful in that it lets the data completely determine the relationship
between the medical images and the variable being predicted. However, this can also be a weakness in that if there
is not enough data to fully capture the uncertainties in a given relationship, ML is very susceptible to overfitting.
MM can help fill in these gaps by encapsulating known relationships and feeding this supplemental knowledge to
the ML model. For this purpose, we make use of the Proliferation-Invasion (PI) model of glioma growth, a model
that can be made patient-specific and has been shown to have significance in predicting radiation sensitivity,
benefit from resection, therapeutic response, and overall survival24–29. We thus refer to our hybrid model as the
ML-PI model.
Following this introduction, we provide a brief background on the ML algorithms used and the PI model. We
then present our methods including a succinct overview of how we combine the ML and PI models to form a
single hybrid model. We then show the accuracy of our hybrid model is better than when compared to predictions
from ML or PI alone. We also determine the significant contributing features to the ML-PI model demonstrating
that the hybrid approach is critical to the success of this model.

Methods

Patient recruitment. Patients were recruited with clinically suspected GBM undergoing preoperative stere-

otactic MRI for first-line surgical resection prior to any treatment, as per the institutional review board approved
protocol “Improving Diagnostic Accuracy in Brain Patients Using Perfusion MRI” at Barrow Neurological
Institute (BNI). All patients provided written, informed consent prior to enrollment following the protocol procedures approved by BNI’s IRB. Data was collected and all protocol procedures were carried out in accordance with
relevant guidelines and regulations. The patient cohort presented here has also been described in previous studies19,20. 82 biopsy samples were collected from 18 GBM patients, with each patient having 2–14 biopsy samples.

Surgical biopsy.

Pre-operative conventional MRI, including T1-Weighted gadolinium contrast-enhanced
(T1Gd) and T2-Weighted sequences (T2W), was used to guide biopsy selection. Each neurosurgeon collected an
average of 5–6 tissue specimens from each tumor by using stereotactic surgical localization, following the smallest
possible diameter craniotomies to minimize brain shift. Specimens were collected from both enhancing mass (as
seen on T1Gd) and non-enhancing brain around tumor (BAT), as seen on T2W, for each tumor. The neurosurgeons recorded biopsy locations via screen capture to allow subsequent coregistration with multiparametric MRI
datasets. The biopsy tissue specimens were reviewed blinded to diagnosis by a neuropathologist and assessed for
tumor content. Taking into account all visible cells (neurons, inflammatory cells, reactive glia, tumor cells, etc.),
the percent tumor nuclei were estimated by a board-certified neuropathologist. Additional details of methods for
surgical biopsy and pathological density measurement can be found in19.

Multiparametric MRI and ROI segmentation.

We included six multiparametric images in the present
study, including T1Gd, T2W, dynamic contrast enhancement (EPI + C), mean diffusivity (MD), fractional anisotropy (FA), and relative cerebral blood volume (rCBV) (detailed MRI protocols and image co-registration can be
found in19 and the Supplementary Information). The T2W ROI, region encompassing the abnormality on both
the T2W and T1Gd images, of each tumor was manually segmented by a board-certified neuroradiologist as the
target region for predictions.

PI density estimation. The proliferation-invasion (PI) model aims to capture the most basic understanding
of what cancer is: cells that grow uncontrollably and invade surrounding tissue. Mathematically, the PI model is
written as follows:
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Figure 1. Workflow of building ML-PI and using the model to generate a predicted cell density map for the
T2W ROI of each tumor/patient. Image-localized biopsies and multiparametric MRIs were collected for each
patient in our study. The images were all co-registered and the voxel corresponding to the biopsy location
was identified. PI-model Volumes of abnormality observed on T1Gd and T2 images were calculated via
segmentation and were used to tune the PI model for each patient to provide a PI prediction of the tumor cell
density. Labeled Samples For each image-localized biopsy, the mean intensity was calculated for each image
sequence and PI cell density prediction corresponding to an 8 × 8 voxel window centered at the biopsy location.
Unlabeled Samples A representative slice from the MRIs was selected. This slice was chosen such that it did not
contain an image-localized biopsy location. The region of interest was segmented by a neuro-radiologist (LH)
on this slice and a mean intensity from each MRI sequence and PI cell density was calculated from an 8 × 8
voxel window corresponding to every voxel contained within the region of interest. Hybrid Model These mean
intensities from both labeled and unlabeled samples were used in the training of our hybrid ML-PI model.
Validation tests were done using labeled sample data only.
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where c(x, t) is the tumor cell density, D(x) is the net rate of diffusion taken to be piecewise constant with different
values in gray and white matter, ρ is the net rate of proliferation and K is the cell carrying capacity. This model
has been used to predict prognosis30, radiation sensitivity27, benefit from resection9, and IDH1 mutation status31.
Additionally, this model was used to create untreated virtual controls for use in defining response metrics that are
more prognostically significant than those currently in use28,32.
Using the T1Gd and T2W images of each patient as input, a D and ρ value were computed for each patient33;
these values were then used to produce a voxel-wise density estimation co-registered to the other images through
the algorithm outlined in34.

Image feature computation. An 8 × 8 voxel box was placed at the location of co-registered images and the

PI-density map that corresponds to each biopsy sample. The average gray-level intensity over the 64 voxels within
the box was computed for each image sequence as was the average PI-predicted tumor cell density. An additional
slice of the MRI sequences was chosen for each patient from which we acquired unlabeled samples. The slice was
selected such that the cross-section included a balanced amount of enhancing mass and non-enhancing BAT.
8 × 8 voxel boxes were placed one pixel apart on the T2W ROI of the chosen slice, and the average gray-level
intensity and PI-predicted tumor cell density were calculated for each of these unlabeled samples, analogous to
the labeled samples.

Data augmentation by synthetic biopsies. As tissue is primarily acquired from regions suspected to be
tumorous, the labeled samples were biased towards higher tumor cell densities (shown in Fig S1(a)). To provide
a balanced dataset for ML-PI model training, synthetic biopsies, taken from regions expected to be low in tumor
cell density, were identified for each patient (if necessary) to be included among the labeled data points. A total
of 39 synthetic biopsy samples were added with each patient having 0–6 samples. Synthetic biopsies were treated
in the same manner as the original labeled data for model training purposes. It is important to note that the synthetic biopsies were only used in model training, and not in validation of the model performance.
Hybrid model development. Our hybrid model is comprised of two parts a semi-supervised learning
approach and a mechanistic model. The general overview of the model is shown in Fig. 1.
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Semi-supervised learning (SSL). SSL has been widely used in applications in which labeled data are scarce but
unlabeled data are available in large quantity, such as in our case in which there are very few biopsy-associated
MRI voxels but numerous non-biopsy associated voxels. There are many types of SSL algorithms, but here we
utilize a graph-based algorithm as presented in35 as our baseline model because of its proven high accuracy and
efficiency in various applications, as well as its inductive learning ability that allows the trained model to be used
to predict new patients. The core idea is to construct a graph with vertices being labeled and unlabeled samples in
a training set and edges weighted by vertex proximity in the feature space.
Mechanistic Proliferation-Invasion (PI) model for patient-specific tumor cell density estimation. The vast majority of the clinically relevant PI literature, model discussed above, focuses on the intuition derived from the
patient-specific parameter values (D and ρ), i.e. the gross tumor growth profile, rather than a voxel by voxel cell
density prediction. This is exactly because the PI model smooths local regional cell density differences on this
scale. The use of the PI model cell densities in the hybrid model presented here is for a similar purpose: these
predictions provide an insight into the expected overall pattern but need to be augmented by more sophisticated
data-driven ML methods to achieve local accuracy. That is, the biological insights provided by the PI model provide a means to regularize the ML models for tumor cell invasion.
Hybrid Model. The key concept in the creation of the hybrid ML-PI model is to incorporate PI-estimated
regional cell density and imaging information from unbiopsied regions into a graph-based SSL. Briefly, it can be
written mathematically as the solution to the following minimization problem:
Error in Biopsied Samples
 Prediction
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This model is an expansion from a typical supervised model, which would be composed of just the first two
terms in eq. (1), by the third term incorporating the PI predictions and imaging information from unbiopsied
regions. In this model, L is the number of biopsy samples in a training dataset. yl is the pathologically measured
tumor cell density for the l-th sample. xl = (zl, PIl), where zl contains gray-level intensity of each MRI sequence
and PIl is the PI predicted cell density (both zl and PIl contain values averaged over the 8 × 8 voxel box placed at
the l-th biopsy sample location). f(xl) is a predictive function for cell density. || ⋅ ||2K is a norm on the reproducing
kernel Hilbert space K . γA and γl are tuning parameters. f contains predictive density for each labeled and unlabeled sample, i.e., given U is the number of unlabeled samples, f = (f(x1), …, f(xL), f(xL+1), …, f(xL+U))T. Ω is a
Laplacian matrix encoding the graph by holding the edge weight and connection information. Finally, wij are the
edge weights between vertices vi and vj, i, j = 1, …, L + U, of the graph capturing the relative difference in MRI
features (wij,z) and PI predictions (wij,PI) can be computed using a product of two Gaussian functions, i.e.,
 ||z − z ||
i
j
wij = wij , z × wij , PI = exp−

2ψz2
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It can be shown, see Supplementary Information, that a solution to (1) exists and that it takes the form:
f ⁎ ( x) =

L +U

∑

i=1

α i K (x i , x),

(3)

−|| x i− x j||2 /2η 2

for coefficients αi and radial basis function kernel K (x i , x j) = e
with tuning parameter η defining the
width of the basis function. The αi’s can be determined analytically in terms of the three tuning parameters γA, γl,
and η. This model and solution are discussed with much more detail and rigor in the Supplementary Material.

Parameter Tuning.

The hybrid ML-PI model includes three parameters that need to be tuned: γA, which
weights the kernel smoother, γI, which weights the influence of unbiopsied regions and PI cell density prediction,
and η, which is the width of the radial basis function kernel. The tuning ranges used were γI, γA ∈ {10−10, …, 104};
η ∈ {10−1, …, 102}. We compared two tuning strategies: patient-specific tuning and uniform tuning. The former
finds the optimal tuning parameters for each patient while the latter assumes the same optimal tuning parameters
across all patients.
Patient-Specific Tuning. To individualize an ML-PI model for each patient, we utilized only the training samples
from the other patients in the first term of Eq. (1). No real or synthetic biopsy samples from the target patient were
used in training in order to avoid overfitting. Then, the trained model was used to predict the real biopsy samples
of the target patient. The optimal tuning parameters were those that minimized the mean absolute prediction
error (MAPE) of the real biopsies on the target patient. Selected parameters are given in Table S2.
Uniform Tuning. To find a single ML-PI model that could be applied to any patient, we looked for a single set of
tuning parameters that minimized the MAPE across all patients. Thus, all patient samples were utilized in the first
term of Eq. (1). Selected parameters are given in Table S3.
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All Samples

BAT Samples Only
Pearson
Correlation

MAPE ± SD

Pearson
Correlation

MAPE ± SD

Patient-Specific ML-PI

0.106 ± 0.125

0.838

0.132 ± 0.118

0.820

Uniform ML-PI

0.176 ± 0.177

0.588

0.195 ± 0.179

0.504

PI

0.227 ± 0.215

0.437

0.204 ± 0.204

0.416

ML

0.199 ± 0.186

0.518

0.233 ± 0.209

0.208

Table 1. Prediction accuracy of all models: Patient-specific ML-PI, Uniform ML-PI, PI only, and ML only.
Accuracy is considered for both cases of utilizing all samples or samples from the BAT only.

Figure 2. Illustrative spatial prediction maps resulting from three different models for two different patients.
Red to blue colors represent 100–0% density. Models presented are the patient-specific hybrid ML-PI, the PI,
and the ML. The weight given to the third term in Eq. (1) helps the hybrid model prediction to keep the general
shape of the PI prediction and use information from unbiopsied regions, while the first term encourages
accuracy in the prediction of biopsy samples and the second term promotes model stability/generalizability.

Feature contribution analysis for ML-PI. To quantify the contribution of each feature, i.e. the mean
image intensities and PI-estimated density, to the prediction made by ML-PI, we developed a modified Relief
algorithm36, which we call “Relief-ML-PI”. This algorithm is run as a post-processing step and results in a score
for each imaging feature x, s(x), that represents the contribution of x. Given i and ir are samples in the training
data set where ir is the rth nearest neighbor of i on the graph G, ŷi and ŷi are the predicted cell density of the two
r
samples by ML-PI, ŷi and ŷi which correspond to feature measurements of x, xi and x i r, we define s(x) as the difr
ference between two probabilities, i.e.,

(

s(x ) = P xi and x i rare different yˆi and yˆi are different

(

r

)

)

− P xi and x i rare different yˆi and yˆi are similiar .
r

(4)

The first term represents the probability that feature x is able to separate samples with different prediction
values, while the second term represents the probability that x separates samples with similar prediction values.
The larger the first probability and/or the smaller the second, the higher the s(x). Further discussion of this metric
and our algorithm for computing the values is provided in the supplement.

Results

Difference in accuracy for different tuning strategies.

In order to determine the degree to which
patient difference would influence the optimal tuning parameters of ML-PI, we first compared the accuracy of
ML-PI between the two training strategies, patient-specific and uniform. Table 1 shows the comparison result
using two metrics: MAPE and Pearson correlation between the predicted and pathological cell density measurements. Both metrics allowed for a 5% error margin in the pathological measurement, i.e., if a predicted value
is within ±5% of the pathological measurement, the prediction is considered correct (i.e., with zero prediction
error). A MAPE of 0.106 means that if the pathologically measured density of a sample is b% (0 ≤ b ≤ 100), the
predicted density by ML-PI deviates from b% by 10.6% on average. From Table 1 it is clear to see that patient-specific tuning has a significantly better accuracy than uniform tuning in terms of both a smaller MAPE (p < 0.0025)
and a higher Pearson correlation (p < 0.001).
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Figure 3. Prediction versus truth correlation plots. Here we show the scatter plots of prediction vs truth
coming from three models, patient-specific ML-PI (top row), PI only (middle row) and ML only (bottom
row). The plots in the left column include all 82 biopsy samples and the ML-PI and ML models were trained
using all available samples. The plots in the right column include the prediction on only the 33 biopsy samples
originating in the non-enhancing (BAT) region. The r value denotes the Pearson correlation coefficient.
Correlation values for both columns are the highest for the patient-specific ML-PI model and significantly
better than those corresponding to PI and ML alone (in both all samples and samples from BAT only). The
p-values in the ML and PI plots correspond to comparing the model’s correlation to the correlation of the
corresponding patient-specific ML-PI.

Hybrid model more accurate than individual models. The output from each of these models is a spa-

tially varying map of tumor cell density. Figure 2 provides illustrative examples of these for two patients. In Fig. 2,
one can also see the effect on the prediction of combining the ML and PI models. It can be observed that the map
by ML-PI generally conforms to the global shape of the PI map, but regional variations are allowed making its
predictions more accurate than using PI and ML alone.
All Samples. We wanted to test the performance of ML-PI against PI and ML used alone. The ML model is a
supervised learning model that takes the same form of ML-PI except with γI = 0, i.e., a model that does not leverage unlabeled data. Table 1 shows the MAPE and Pearson correlation and Fig. 3 shows the plots of the predicted
vs. pathological tumor cell density for each model. Compared with the patient-specific ML-PI, PI and ML alone
had a significantly worse accuracy in terms of both MAPE and Pearson correlation (p < 0.001 in all comparisons).
Also, we present the patient-wise MAPEs of ML-PI, PI, and ML in Table S1, found in the Supporting Information,
to allow for comparison on the patient-level. ML-PI was able to predict more accurately than ML and PI in 17 out
of 18 patients.
Brain Around Tumor (BAT) Samples Only. The BAT region is clinically interesting as that is most challenging
to interpret through the obscured lens of MRI. Therefore, we further compared the performance of ML-PI, PI,
and ML on predicting the tumor density of samples in the BAT. Out of the 82 total samples, 33 are in this area.
The right two columns of Table 1 show the MAPE and Pearson correlation of each model and Fig. 3 additionally
shows the predicted vs. pathological tumor cell density of the 33 samples for each of the three models. One can
see from both Table 1 and Fig. 3 that ML-PI significantly outperforms PI and ML within the BAT region in all the
comparisons (p < 0.05).

Importance of Individual Tuning Parameters. We further investigated which of the three tuning parameters have a greater effect on model accuracy when allowed to be patient-specific. To achieve this purpose, we
added a third tuning strategy, partially-uniform tuning, in which two of the three tuning parameters were kept
the same across all patients while the remaining one was allowed to vary from patient to patient. This results in
three models corresponding to γA, γI, or η as the parameter allowed to be patient-specific, respectively. Table 2
shows the performance of the three models. Compared with the result of uniform tuning in Table 1, we see
patient-specific tuning of γA resulted in a significantly improved MAPE and Pearson correlation (p = 0.023 and
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Parameter allowed to be patient-specific
γA

γI

MAPE ± SD

0.127 ± 0.129

0.156 ± 0.154

η
0.140 ± 0.153

Pearson correlation

0.792

0.676

0.713

Table 2. Prediction accuracy of ML-PI with partially-uniform tuning.

Figure 4. Contributions of PI and MRI sequences to ML-PI cell density prediction.

0.011). While patient-specific tuning of either η (p = 0.087 and 0.17)or γI (p = 0.22 and 0.35) alone does not result
in a significantly improved MAPE and Pearson correlation. Selected tuning parameters are listed in Table S4.

Contributions from MRI sequences and PI. Using Relief-ML-PI, we can compute a contribution score
for each image feature (one feature per MRI sequence) and PI from the ML-PI model specific to each patient.
To identify the contributions aggregated over all the patients, we normalize the score of each feature within each
patient to be between 0 and 1 by dividing the score by a sum over the scores of all the features. Then, the normalized scores from each patient are added together to produce an aggregated score showing contribution from each
feature. Figure 4 shows the contribution from each MRI sequence and PI. It is clear that PI contributes the most.

Conclusion

Despite the vast amounts of data being collected for individual patients, the promise of personalized medicine still
remains to be fully realized. Data driven, machine learning processes provide a way to harness more and more of
the incoming data. However, in the case of cancer, this avalanche of data still only represents limited snapshots of
small regions of a complex, heterogeneous, and adapting system. Thus, machine learning models continue to be
highly susceptible to overfitting and are notorious for not yielding reproducible results37–39. Mechanistic models
can help guide machine learning models by providing information regarding the overarching principles guiding
the system. This paper represents a key broad first step in demonstrating how combining these methodologies to
achieve better results can be done.
In this paper, we have proposed a hybrid model leveraging principles from both machine learning and mechanistic models, the ML-PI model. This model aims to provide patient-specific spatial maps of tumor cell density within
a given GBM patients’ brain for enhanced surgical and radiation therapy planning. This hybrid model leverages
multiparametric MRI and PI tumor cell density predictions under a graph-based SSL framework. Both parameter
tuning methods for the ML-PI model, patient-specific and uniform, were able to outperform the PI model alone and
the ML model alone. Of note, the patient-specific tuning statistically significantly outperformed the other models,
achieving a MAPE score of 0.1 and a correlation coefficient of 0.84 between predicted and true values. The importance of the hybrid paradigm was further emphasized through our Relief-ML-PI algorithm, which revealed that the
PI tumor cell density prediction contributed most significantly to the prediction of all the included image features.
There are certainly limitations to the results presented in this paper. First and foremost, while the dataset is
novel, it is small and only includes primary GBM patients. Thus, a leave-one-patient out framework was used as
an initial validation check, but more data is certainly needed to supply a richer training and testing ground for
this model and to explore the applicability of our model in the recurrent setting. Second, our model depends on
six distinct MRI sequences, which are not all standardly acquired and some of which, e.g. perfusion, are known to
vary significantly from institute to institute. Thus, the GBM patient population for which our model can be immediately utilized is limited. In future studies, we intend to study the decrease in accuracy as sequence requirements
are removed in hopes of identifying a model that can be more broadly deployed. Third, the best accuracy was
achieved for the patient-specific ML-PI, which does require a patient to already have had a biopsy in order for the
prediction to be made. This certainly limits its ability to aid in surgical planning, but does not impact its potential
usefulness in sculpting the dose map for radiation therapy. Further, we note that while the uniform model was not
as accurate, it still outperformed the PI and ML models alone and could provide an initial prediction for an active
sampling method to guide surgeons during surgery.
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It is well accepted that GBM tumor cells exist beyond the enhancement observed on T1Gd MRI, the main surgical target. Radiation dose plans, implemented after surgery, try to account for this with broad margins of high
dose out 2 cm from the enhancement and lower doses up to 4 cm away. Unfortunately, GBMs uniformly recur
and the location of recurrence is almost always within the field of high dose radiation treatment. We believe the
continued failure of radiation therapy is a direct result of the fact that standard-of-care dose plans and shapes are
driven to be simultaneously aggressive and conservative. They are aggressive in wide margins by the knowledge
that the cells are, but then are conservative in dose delivered due to the uncertainty in their precise location and
the desire to preserve normal brain. We believe that as our model continues to be refined and is hopefully shown
to be reliable, it can be used to better inform dose plans to be precisely aggressive and precisely conservative.
We are continuing to accrue patients from multiple institutions to our study to increase our dataset both in
size and diversity. Future work will encompass retraining and testing our models with these new datasets and
investigating possible other critical information that may produce more accurate models such as patient sex or
tumor location. Should our model prove reliable, it will help localize invasive tumor populations within the otherwise non-specific T2W regions to better inform resection and radiation therapy, potentially increasing overall
survival for GBM patients.

Data Availability

The datasets generated during and/or analyzed during the current study are not publicly available due to institutional review board requirements but are available from the corresponding author on reasonable request.
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